Trental is the brand name for pentoxifylline, a prescription medication FDA-approved to treat intermittent claudication, the cramping leg pain that occurs during walking when arteries in the legs are narrowed or blocked. It works by improving blood flow rather than opening the arteries themselves, making it easier to walk longer distances with less pain.
How Trental Treats Leg Pain From Poor Circulation
Intermittent claudication is the hallmark symptom of peripheral artery disease (PAD). Fatty deposits build up inside leg arteries, restricting blood flow to the muscles. When you walk or climb stairs, your leg muscles need more oxygen than the narrowed arteries can deliver, causing aching, cramping, or heaviness, usually in the calves. The pain stops when you rest.
Trental doesn’t widen the arteries or remove blockages. Instead, it changes the physical properties of blood so it flows more easily through narrowed vessels. In clinical trials, the standard dose of 400 mg taken three times daily increased maximum walking distance by about 33 meters compared to placebo. That may sound modest, but for someone who has to stop every block or two, it can meaningfully expand how far they can walk before pain forces them to rest. Pain-free walking distance improved by roughly 15 meters on average.
The FDA label notes that Trental improves function and symptoms but is not meant to replace more definitive treatments like surgical bypass or procedures to physically clear blocked arteries. It’s typically used alongside lifestyle changes, especially a structured walking program, which remains the cornerstone of claudication treatment.
How It Works in the Body
Trental belongs to a class of compounds called methylxanthines (related to caffeine) and affects blood flow through several overlapping mechanisms. It makes red blood cells more flexible, allowing them to squeeze through tiny capillaries more easily. It reduces the stickiness of platelets, lowering their tendency to clump together. And it decreases the thickness of both blood plasma and whole blood, partly by lowering levels of fibrinogen, a protein involved in clotting.
White blood cells play a role too. When certain white blood cells become activated, they stiffen and have trouble passing through the smallest blood vessels. Trental suppresses this activation, keeping them pliable and improving flow at the capillary level. This same effect gives the drug anti-inflammatory and antioxidant properties, since activated white blood cells generate damaging free radicals and release inflammatory signaling molecules. Trental has been shown to lower blood levels of several key inflammatory markers, including TNF-alpha and interleukins 1 and 6.
The net result of all these changes is better circulation through vascular beds downstream from a narrowing, which is exactly where blood flow is most compromised in peripheral artery disease.
How Trental Compares to Other Options
Cilostazol (brand name Pletal) is the other major oral medication for intermittent claudication, and head-to-head comparisons consistently show it outperforms Trental. A network meta-analysis found cilostazol increased maximum walking distance by about 63 meters over placebo, nearly double the 33-meter improvement seen with pentoxifylline. Pain-free walking distance followed the same pattern: 24 meters for cilostazol versus 15 meters for pentoxifylline.
Both drugs are considered effective treatments, but cilostazol is generally ranked as the stronger choice with good tolerability. Your prescriber may choose Trental over cilostazol in certain situations, particularly if you have heart failure, since cilostazol carries warnings for that population that Trental does not.
Off-Label Uses
Because of its anti-inflammatory properties and effects on blood flow, Trental has been tried for a number of conditions beyond leg claudication. One of the more studied off-label uses is severe alcoholic hepatitis, a life-threatening liver condition with an average mortality around 40%. A Cochrane review pooling five randomized trials (336 participants total) found that pentoxifylline reduced overall mortality by about 36% and cut deaths from a specific complication called hepatorenal syndrome by 60%. However, the reviewers cautioned that these results didn’t hold up under stricter statistical testing designed to guard against false positives, so the evidence remains inconclusive.
Trental has also been used off-label for venous leg ulcers, radiation-induced tissue damage, and certain inflammatory skin conditions, though the evidence base for these uses is considerably thinner than for claudication.
What to Expect While Taking It
The standard regimen is one 400 mg extended-release tablet taken three times per day with meals. Clinical trials have lasted up to 60 weeks, and improvement tends to be gradual rather than immediate. Most clinicians recommend giving the medication at least 8 weeks before judging whether it’s working, and some patients don’t notice the full benefit for several months.
Trental is not a quick fix. It’s meant as one part of a broader approach to managing peripheral artery disease that typically includes regular walking exercise, smoking cessation, cholesterol management, and blood pressure control.
Common Side Effects
Digestive symptoms are the most frequent complaint. With the extended-release tablet (the formulation most commonly prescribed today), about 2.8% of patients experience indigestion, 2.2% report nausea, and 1.2% have vomiting. For the nervous system, dizziness affects about 1.9% and headache about 1.2%. These rates are relatively low and reflect the extended-release formulation’s gentler impact on the stomach compared to the older immediate-release capsules, which caused nausea in nearly 29% of patients and dizziness in about 12%.
All of these side effects are dose-related. If digestive upset or dizziness becomes a problem, the dose can be reduced to two tablets per day (800 mg total) instead of three. If symptoms persist at the lower dose, the medication is typically discontinued. Rare side effects reported after the drug reached the market include anxiety, confusion, dry mouth, and constipation, all occurring in less than 1% of patients.